INVESTORS

Operations

Cohera is an early-stage company that intends to position itself as a provider of biomedical adhesives to the medical industry. The Company will begin operations with our R&D focused on the creation of our next-generation products, while subcontracting pre-clinical testing on our lead product, TissuGlu®. The chemistry underlying our product formulation is straightforward and highly scalable, with raw materials readily available in bulk from established suppliers. A GMP (Good Manufacturing Practices) manufacturing facility has been identified for our pilot scale synthesis.

Financing

In August 2006, we completed a Series A financing in which we raised $6.8M from private investors. TissuGlu® has the development costs of a medical device with the returns of a pharmaceutical. Our models indicate that Cohera will achieve breakeven within 18 months of product launch which is expected to occur in 2010.